Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q&A: Merck KGaA Global Head Of Medical Affairs On Pipeline Persistence

Executive Summary

Maria Rivas has been in post as Merck KGaA’s global head of medical affairs for just over a month. She talks to Scrip about her immediate priorities, and the Darmstadt-based company’s potential in immunotherapies and oncology.

You may also be interested in...

Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip

With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.

Merck KGaA R&D Head: Biomarker Approach 'Further Validated' At ASCO

Luciano Rossetti says Germany's Merck is likely to partner M7824 bifunctional immunotherapy, and go solo with tepotinib.

Post-Rebif, Merck KGaA Keeps Faith With MS Therapies

CEO Stefan Oschmann is sticking to his previous forecast of annual peak sales of €500-700m for Mavenclad, excluding the US, and Merck has high hopes for another MS treatment, the BTK inhibitor evobrutinib, following promising Phase IIb data.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts